Aspects of modernizing drug development using clinical scenario planning and evaluation

Drug Information Journal

Volumn 44, Issue 3, 2010, Pages 299-315

  Benda, Norbert ^a   Branson, Michael ^b   Maurer, Willi ^b   Friede, Tim ^c  

^a Federal Institute for Drugs and Medical Devices   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Clinical design optimization; Clinical development plan; Clinical scenario evaluation; Critical path initiative; Modern protocol design; Robustness; Simulation

Indexed keywords

ANALYTIC METHOD; CLINICAL DEVELOPMENT PLAN; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER SIMULATION; DECISION MAKING; DRUG DEVELOPMENT; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SAMPLE SIZE; SIMULATION; STATISTICAL ANALYSIS; STUDY DESIGN;

EID: 78249260148     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151004400312     Document Type: Review

References (24)

1. US Food and Drug Administration. Innovation/ Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. March 2004. Available at http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
2. US Food and Drug Administration. Innovation/ Stagnation: Critical Path Opportunity List. March 2006. Available at http://www.fda.gov/oc/initiatives/ criticalpath/reports/opp list.pdf.
3. European Medicines Agency. Mandate of the EMEA Innovation Task Force (ITF). London, April 2006. Available at http://www.emea.europa.eu/pdfs/human/ itf/itfmandate.pdf.
4. European Medicines Agency. Innovative Drug Development Approaches - Final Report From the EMEA/CHMP-Think-Tank Group on Innovative Drug Development. London, March 2007. Available at http://www.emea.europa.eu/pdfs/human/itf/ 12731807en.pdf.
5. European Medicines Agency. The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future. London, March 2007. Available at http://www.emea.europa.eu/pdfs/general/direct/directory/3416303enF.pdf.
6. O'Neill RT. A perspective on contributions of biostatistics to the critical path initiative. Presentation given at workshop, Model-based Drug Development - A Cornerstone of the FDA's Critical Path Initiative, Basel Biometric Society, December 2004. Available at http://www.psycho.unibas.ch/BBS/ slides/ONeill2.ppt.zip.
7. Allen M. Business Portfolio Management: Valuation, Risk Assessment, and EVA Strategies. New York: John Wiley; 2000.
8. Sharp P, Keelin T. How SmithKline Beecham makes better resource-allocation decisions. Harvard Bus Rev. 1998 (March).
9. Adam CW, Gupta P, Wilson CE. Six Sigma Deployment. Burlington, VT: Butterworth-Heinemann; 2003.
10. European Medicines Agency. Points to Consider on the Evaluation of Medicinal Products for the Treatment of Irritable Bowel Syndrome. Doc. Ref. EMEA/ CPMP/EWP/785/97, Committee for Proprietary Medicinal Products (CPMP), London, March 2003.
11. Armitage P. Interim analysis in clinical trials. Stat Med. 1991;10:925-937.
12. Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Stat Med. 1999;18:1833-1848.
13. Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics. 1994; 50:1029-1041. Correction in Biometrics. 1996; 52:380.
14. Bretz F, Schmidli H, König F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biometric J. 2006;48:623-634. (Pubitemid 44367905)
15. Schmidli H, Bretz F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim. Part II: applications and practical considerations. Biometric J. 2006;48:635-643. (Pubitemid 44367906)
16. Kimani PK, Stallard N, Hutton J. Dose selection in seamless phase II/III clinical trials based on efficacy and safety. Stat Med. 2009;28:917-936.
17. König F, Bauer P, Brannath W. An adaptive hierarchical test procedure for selecting safe and efficient treatments. Biometric J. 2006;48:663-678.
18. MacDonald TM, Reginster JY, Littlejohn TW, et al. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J Hypertension. 2008;26:1695-1704.
19. Chuang-Stein C, Anderson K, Gallo P, Collins S. Sample size reestimation: a review and recommendations. Drug Inf J. 2006;40:475-484. (Pubitemid 44721125)
20. Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review. Biometric J. 2006;48:537-555. (Pubitemid 44367892)
21. European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. Section 4.2.2. Doc. Ref. EMEA/CPMP/EWP/ 2459/02, Committee for Medicinal Products for Human Use (CHMP), London, October 18, 2007.
22. Kieser M, Friede T. Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Stat Med. 2003;22:3571-3581. (Pubitemid 37483535)
23. ICH-E1. ICH Topic E1. Population Exposure: The Extent of Population Exposure to Assess Clinical Safety. 1995. Available at http://www.ema.europa.eu/ pdfs/human/ich/037595en.pdf.
24. Koch G, Tangen C, Jung JW, Amara I. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Stat Med. 1998;17:1863-1892. (Pubitemid 28409938)